Expert Interview
A Third Opinion: An updated look at the phase 2 data from Boehringer Ingelheim's and Zealand Pharmaceuticals Survodutide for the treatment of MASH.
Ticker(s): BOEHRINGER INGELHEIM, ZEALInstitution: Stanford University
- Pediatric gastroenterologist specializing in IBD
- treats 10-20 patients per year with PSC (mostly IBD-associated PSC)
- familiar with the publicly available data from the Phase 2a INTEGRIS-PSC clinical trial of bexotegrast in patients with PSC and suspected moderate to severe liver fibrosis
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
